Login
$PTHS
$7.15 +$0.00 (0.0%) After hours

$PTHS SEC Filings

Filed On Filing
16 Nov 2026 D
12 Nov 2026 425
12 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 S-8
12 Nov 2026 S-8 POS
12 Nov 2026 S-8 POS
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025

03 Nov 2026 SCHEDULE 13D/A
30 Oct 2026 425
30 Oct 2026 425
30 Oct 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +6 more

Form of Amended and Restated Limited Liability Company Agreement of the Surviving Company

06 Oct 2026 Form 4: Greenleaf Peter, Director

Sold 797 shares ($16.9K)

06 Oct 2026 Form 4: Friedberg Ezra M, Director

Sold 558 shares ($11.6K)

06 Oct 2026 Form 4: Pauls Matthew, Director

Sold 786 shares ($16.5K)

01 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(a) The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to encourage key service providers of Pelthos Therapeutics Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by ...

18 Aug 2026 ARS
18 Aug 2026 DEFA14A
18 Aug 2026 Proxy statement: annual meeting on September 29, 2026
13 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support